Structural and functional characterization of C0021158, a high-affinity monoclonal antibody that inhibits Arginase 2 function via a novel non-competitive mechanism of action.

ARG2 ARG2 epitope ARG2 neutralization Arginase 2 antibody co-crystal structure cancer therapeutics human monoclonal antibody phage display selections

Journal

mAbs
ISSN: 1942-0870
Titre abrégé: MAbs
Pays: United States
ID NLM: 101479829

Informations de publication

Date de publication:
Historique:
entrez: 4 9 2020
pubmed: 4 9 2020
medline: 6 7 2021
Statut: ppublish

Résumé

Arginase 2 (ARG2) is a binuclear manganese metalloenzyme that catalyzes the hydrolysis of L-arginine. The dysregulated expression of ARG2 within specific tumor microenvironments generates an immunosuppressive niche that effectively renders the tumor 'invisible' to the host's immune system. Increased ARG2 expression leads to a concomitant depletion of local L-arginine levels, which in turn leads to suppression of anti-tumor T-cell-mediated immune responses. Here we describe the isolation and characterization of a high affinity antibody (C0021158) that inhibits ARG2 enzymatic function completely, effectively restoring T-cell proliferation

Identifiants

pubmed: 32880207
doi: 10.1080/19420862.2020.1801230
pmc: PMC7531564
doi:

Substances chimiques

Single-Chain Antibodies 0
ARG2 protein, human EC 3.5.3.1
Arginase EC 3.5.3.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Pagination

1801230

Subventions

Organisme : Cancer Research UK
ID : C1362/A20263
Pays : United Kingdom

Références

Mol Cancer Ther. 2012 Jul;11(7):1467-76
pubmed: 22564724
Chem Biol Drug Des. 2006 Jan;67(1):83-4
pubmed: 16492153
Biochem J. 1998 Nov 15;336 ( Pt 1):1-17
pubmed: 9806879
Gene. 1997 Mar 10;187(1):9-18
pubmed: 9073061
J Med Chem. 2006 Jan 26;49(2):534-53
pubmed: 16420040
Science. 2004 Sep 17;305(5691):1770-3
pubmed: 15319492
Med Res Rev. 2017 May;37(3):475-513
pubmed: 27862081
Cancer Res. 2015 Aug 1;75(15):3043-53
pubmed: 26054597
Immunotherapy. 2017 Jan;9(1):83-97
pubmed: 28000524
EMBO J. 1998 Jul 1;17(13):3512-20
pubmed: 9649422
Nat Struct Biol. 1999 Nov;6(11):1043-7
pubmed: 10542097
J Mol Biol. 1992 Aug 5;226(3):889-96
pubmed: 1507232
Nature. 1996 Oct 10;383(6600):554-7
pubmed: 8849731
Proc Natl Acad Sci U S A. 2020 Jul 21;117(29):16949-16960
pubmed: 32616569
Nat Commun. 2017 Aug 14;8(1):242
pubmed: 28808255
J Immunol. 1991 Sep 1;147(5):1709-19
pubmed: 1908882
Biochemistry. 2003 Jul 22;42(28):8445-51
pubmed: 12859189
Proc Natl Acad Sci U S A. 2016 Dec 27;113(52):14970-14975
pubmed: 27965386
Acta Crystallogr D Biol Crystallogr. 2014 Sep;70(Pt 9):2430-43
pubmed: 25195756
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):355-67
pubmed: 21460454
J Synchrotron Radiat. 2006 May;13(Pt 3):227-38
pubmed: 16645249
Nat Rev Immunol. 2005 Aug;5(8):641-54
pubmed: 16056256
Blood. 2013 Aug 1;122(5):749-58
pubmed: 23733335
Dev Comp Immunol. 2019 Jan;90:100-107
pubmed: 30236879
Biochemistry. 1994 Sep 6;33(35):10652-7
pubmed: 8075066
J Immunol Methods. 2006 Jun 30;313(1-2):129-39
pubmed: 16730741
J Hematol Oncol. 2008 Sep 25;1:14
pubmed: 18817562
Bioinformatics. 2008 Sep 1;24(17):1953-4
pubmed: 18641403
Acta Crystallogr D Biol Crystallogr. 2004 Mar;60(Pt 3):610-2
pubmed: 14993709
Nat Biotechnol. 1996 Mar;14(3):309-14
pubmed: 9630891
JCI Insight. 2019 Nov 21;4(24):
pubmed: 31751318
Blood. 2015 Jun 25;125(26):4060-8
pubmed: 25896651
Acta Crystallogr D Biol Crystallogr. 2010 Apr;66(Pt 4):486-501
pubmed: 20383002
J Intern Med. 2016 Jun;279(6):541-62
pubmed: 26748421
Cancer Immunol Immunother. 2019 Apr;68(4):645-660
pubmed: 30003321
Annu Rev Immunol. 2007;25:267-96
pubmed: 17134371
Nat Rev Cancer. 2006 Sep;6(9):714-27
pubmed: 16929325
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):125-32
pubmed: 20124692
Br J Pharmacol. 2019 Jan;176(1):52-66
pubmed: 29488211
Bioorg Med Chem. 2006 May 1;14(9):3160-73
pubmed: 16413785
Acta Crystallogr D Biol Crystallogr. 2013 Jul;69(Pt 7):1204-14
pubmed: 23793146
Nat Med. 2011 Dec 25;18(1):143-7
pubmed: 22198278
Curr Opin Immunol. 2016 Apr;39:1-6
pubmed: 26609943
J Med Chem. 2013 Mar 28;56(6):2568-80
pubmed: 23472952
J Immunother Cancer. 2017 Dec 19;5(1):101
pubmed: 29254508
PLoS One. 2013;8(2):e55146
pubmed: 23424623
EPMA J. 2015 Nov 27;6:23
pubmed: 26617680
Appl Biochem Biotechnol. 1994 May-Jun;47(2-3):157-71; discussion 171-3
pubmed: 7944335
Biochem Biophys Res Commun. 1994 Jul 15;202(1):174-80
pubmed: 8037711
Tumour Biol. 2017 Jul;39(7):1010428317712512
pubmed: 28718378
MAbs. 2009 Nov-Dec;1(6):552-62
pubmed: 20068388
J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674
pubmed: 19461840
J Chem Theory Comput. 2011 Jul 12;7(7):2284-95
pubmed: 26606496
Cancer Res. 2004 Aug 15;64(16):5839-49
pubmed: 15313928
Protein Eng Des Sel. 2009 Mar;22(3):159-68
pubmed: 18974080
FASEB J. 2013 Feb;27(2):581-9
pubmed: 23104982
Molecules. 2019 Jun 18;24(12):
pubmed: 31216704

Auteurs

Mark Austin (M)

Cancer Research UK AstraZeneca Antibody Alliance Laboratory , Cambridge, UK.
Antibody Discovery & Protein Engineering, BioPharmaceuticals R&D, AstraZeneca , Cambridge, UK.

Daniel Burschowsky (D)

Leicester Institute of Structural and Chemical Biology and the Department of Molecular and Cell Biology, University of Leicester , Leicester, UK.

Denice T Y Chan (DTY)

Cancer Research UK AstraZeneca Antibody Alliance Laboratory , Cambridge, UK.

Lesley Jenkinson (L)

Cancer Research UK AstraZeneca Antibody Alliance Laboratory , Cambridge, UK.

Stuart Haynes (S)

Cancer Research UK AstraZeneca Antibody Alliance Laboratory , Cambridge, UK.

Agata Diamandakis (A)

Cancer Research UK AstraZeneca Antibody Alliance Laboratory , Cambridge, UK.

Chitra Seewooruthun (C)

Leicester Institute of Structural and Chemical Biology and the Department of Molecular and Cell Biology, University of Leicester , Leicester, UK.

Alexandra Addyman (A)

Cancer Research UK AstraZeneca Antibody Alliance Laboratory , Cambridge, UK.

Sebastian Fiedler (S)

Cancer Research UK AstraZeneca Antibody Alliance Laboratory , Cambridge, UK.

Stephanie Ryman (S)

Cancer Research UK AstraZeneca Antibody Alliance Laboratory , Cambridge, UK.

Jessica Whitehouse (J)

Cancer Research UK AstraZeneca Antibody Alliance Laboratory , Cambridge, UK.

Louise H Slater (LH)

Cancer Research UK AstraZeneca Antibody Alliance Laboratory , Cambridge, UK.

Andreas V Hadjinicolaou (AV)

MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford , Oxford, UK.

Uzi Gileadi (U)

MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford , Oxford, UK.

Ellen Gowans (E)

Cancer Research UK AstraZeneca Antibody Alliance Laboratory , Cambridge, UK.

Yoko Shibata (Y)

Cancer Research UK AstraZeneca Antibody Alliance Laboratory , Cambridge, UK.

Michelle Barnard (M)

Cancer Research UK AstraZeneca Antibody Alliance Laboratory , Cambridge, UK.

Teresa Kaserer (T)

Cancer Research UK, Cancer Therapeutics Unit, The Institute of Cancer Research , London, UK.

Pooja Sharma (P)

Cancer Research UK AstraZeneca Antibody Alliance Laboratory , Cambridge, UK.

Nadia M Luheshi (NM)

Early Oncology Discovery, Oncology R&D, AstraZeneca , Cambridge, UK.

Robert W Wilkinson (RW)

Early Oncology Discovery, Oncology R&D, AstraZeneca , Cambridge, UK.

Tristan J Vaughan (TJ)

Antibody Discovery & Protein Engineering, BioPharmaceuticals R&D, AstraZeneca , Cambridge, UK.

Sarah V Holt (SV)

Cancer Research UK AstraZeneca Antibody Alliance Laboratory , Cambridge, UK.

Vincenzo Cerundolo (V)

MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, University of Oxford , Oxford, UK.

Mark D Carr (MD)

Leicester Institute of Structural and Chemical Biology and the Department of Molecular and Cell Biology, University of Leicester , Leicester, UK.

Maria A T Groves (MAT)

Cancer Research UK AstraZeneca Antibody Alliance Laboratory , Cambridge, UK.
Antibody Discovery & Protein Engineering, BioPharmaceuticals R&D, AstraZeneca , Cambridge, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH